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Abstract
BACKGROUND
There is no human epidemiology data available to estimate the heavy ion 
cancer risks experienced by astronauts in space.  Studies of tumor induction in 
mice are a necessary step to estimate risks to astronauts.  Previous 
experimental data can be better utilized to model dose response for heavy ion 
tumorigenesis and plan future low dose studies.  
DOSE RESPONSE MODELS
The Harderian Gland data of Alpen et al.[1-3] was re-analyzed [4] using non-
linear least square regression.  The data set measured the induction of 
Harderian gland tumors in mice by high-energy protons, helium, neon, iron, 
niobium and lanthanum with LET’s ranging from 0.4 to 950 keV/micron.  We 
were able to strengthen the individual ion models by combining data for all ions 
into a model that relates both radiation dose and LET for the ion to tumor 
prevalence.  We compared models based on Targeted Effects (TE)  to one 
motivated by Non-targeted Effects (NTE)  that included a bystander term that 
increased tumor induction at low doses non-linearly. When comparing fitted 
models to the experimental data, we considered the adjusted R2, the Akaike 
Information Criteria (AIC), and the Bayesian Information Criteria (BIC) to test for 
Goodness of fit. In the adjusted R2 test, the model with the highest R2 values 
provides a better fit to the available data.  In the AIC and BIC tests, the model 
with the smaller values of the summary value provides the better fit.  The non-
linear NTE models fit the combined data better than the TE models that are 
linear at low doses.  We evaluated the differences in the relative biological 
effectiveness (RBE) and found the NTE model provides a higher RBE at low dose 
compared to the TE model.
POWER ANALYSIS
The final NTE model estimates were used to simulate example data to consider 
the design of new experiments to detect NTE at low dose for validation.  Power 
and sample sizes were calculated for a variety of radiation qualities including 
some not considered in the Harderian Gland data set and with different 
background tumor incidences.  We considered different experimental designs 
with varying number of doses and varying low doses dependant on the LET of 
the radiation.  The optimal design to detect a NTE for an individual ion had 4 
doses equally spaced below a maximal dose where “bending” due to cell 
sterilization was < 2%.  For example at 100 keV/micron we would irradiate at 
0.03 Gy, 0.065 Gy, 0.13 Gy, and 0.26 Gy and require 850 mice including a control 
dose for a sensitivity to detect NTE with 80% power.  Sample sizes could be 
improved by combining ions similar to the methods used with the Harderian 
Gland data.
Color Categories
Uncertainty Reduction/Risk Mitigation Category Color = Green
Mechanistic/Descriptive Category Color = Light Yellow
Blue Bullets Progress
• Applying a NTE model motivated by the dose response observed for 
bystander effects and genomic instability in cell culture, we show that the 
NTE model provides a superior fit to the dose response for tumors in mice 
based on several model ranking tests. These results add important empirical 
evidence in support of the NTE model based on in vivo data for tumor 
responses.
• We were able to fit models for the LET dependence of tumors over a broad 
range from protons to heavy ions and describe a dose dependent RBE 
applicable to low dose exposures.
• Power analysis based on the Harderian gland data suggest the optimal 
number of mice to be studied for future dose response experiments and 
suggest sample size reductions will occur when results for several radiation 
qualities are combined into a single model.
Red Bullets Gaps in Progress and Knowledge
• The relative contribution to cancer risks from targeted effects and non-
targeted effects remains elusive with too few experiments designed to test 
the shape of the dose response at low doses (<0.3 Gy) applicable to space 
missions.
• Only a few murine model tumors have been studied with only a few ion 
types. The paucity of data limits the building and testing of models of cancer 
risk from space radiation.
• The usage of human cell culture models in 2D or 3D is needed to support the 
applicability of murine models to human risk prediction, however much work 
remains in making the necessary connections. Of importance is the need for 
more expansive data set on radiation quality at a variety of low doses to 
understand the shape of the dose response for cancer processes induced by 
heavy ions.
Ion
Energy 
(MeV/u)
LET 
(keV/μm)
Hydrogen 250 0.4
Helium 228 1.6
Neon 670 25
Iron 600 193
Iron 350 253
Niobium 600 464
Lanthanum 593 953
• Measured Harderian gland tumors in female B6CF1/Anl mice.
• A variety of heavy ions were accelerated at the Lawrence Berkeley 
National Lab for the exposures.
• Mice were irradiated at 100 to 120 days.
• Tumor prevalence was determined 16 months after irradiation.
• Tumor appearance was accelerated using pituitary implants
o Reduced the effects of competing tumor risks and reduced costs of 
experiments (sacrifice at 600 d compared to lifespan of ~900 d)
• Fe nuclei showed same tumor response with or without the 
pituitary implants.
• γ-rays were used as a low-LET reference radiation
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P0 2.64 0.77
α 4.31 3.09
β 5.08 2.25
λ 0.264 0.055
γ-ray TE model relating dose to tumor prevalence
Heavy ion TE model relating dose and LET to tumor prevalence
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P0 2.8 0.48
a0 12.39 2.2
a1 1.17 0.21
a2 0.00369 0.00064
λ0 0.0504 0.0298
λ1 0.0068 0.0029
λ2 0.0033 0.002
Adjusted r2 = 0.9296, AIC = 210, BIC = 222.1
Heavy ion NTE model relating dose and LET to tumor prevalence
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Estimate Standard Error
P0 2.44 0.41
a0 13.60 1.87
a1 0.64 0.21
a2 0.00353 0.00081
λ0 0.055 0.025
λ1 0.0059 0.0055
λ2 0.0055 0.0048
κ1* 0.107 0.054
κ2* 0.0045 0.0020 Adjusted r2 = 0.9514, AIC = 195.9, BIC = 211.6
*P-values are 0.056 and 0.03 respectively.
Description of Alpen data.
Cross-over dose is defined as 
the dose where TE = NTE
A dose dependent relative biological 
effectiveness (RBE) is found in the 
NTE model
Applications of Models for Risk Estimation
Source of tumor data for heavy ions
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• The study focuses on low doses where the cell sterilization 
term can be ignored.
• Parameter estimates from the NTE model were used to 
generate simulations for each ion individually.
• Simulations were analyzed using generalized linear models 
with binomial errors following the low dose model.
• Power was determined by the ability to detect if NT Effects 
(κ) are significant at low dose
• Doses were chosen at 0Gy and 3 or 4 irradiation doses 
chosen as seen in the figure with sample sizes such that all 
doses have equal binomial variances.
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Power Analysis Specifications
• Dosing Schemes for irradiated mice:
1. Three radiation doses (D1, D2, and D3 from figure) were 
considered and d ≈ 2%.
2. Three radiation doses were considered and d ≈ 1%.
3. Four radiation doses (D1, D2, D3, and D4 from figure) 
were considered and d ≈ 2%.
“d” is %-difference between linear 
low dose model (light green) and the 
individual NTE models (dark green)
Scheme 1
P0 = 2.44
Scheme 2
P0 = 2.44
Scheme 3
P0 = 2.44
Scheme 3
P0 = 5
Scheme 3
P0 = 10
Fe,
LET = 193
900 1031 690 810 1069
LET = 100 1200 1180 850 1061 1810
LET = 70 1620 1620 1101 1600 >2100*
Total** 3120 3231 2041 2871 >4379
*Power = 68.27% **Assuming controls same across the 3 ions
Table: Sensitivity of sample size to detect NTE with 80% power to the scheme 
choice and background %-Prevalence (P0).
α λ κ
LET = 70 48.59 0.317 5.47
LET = 100 58.56 0.372 6.82
Fe, 
LET = 193
76.01 0.449 8.62
Table: The LET values chosen for the 
study and parameter estimates 
from the NTE model
Equation: The individual NTE Model
Equation: The linear low dose Model
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Figure: Representation of how 
doses were chosen.  Each additional 
dose is half way between the 
previous dose and 0.
Figure: Doses and sample sizes for Scheme 3 
by individual ions
• Dosing Scheme 3 was optimal.
• More mice are needed as the value of P0 increases.
• The sample size estimates to test for NTE for single 
ions will over-estimate sample size requirements 
when results from several ions are combined into a 
model that describes the LET dependence of the 
tumor response.
Power Analysis Conclusions
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